{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T05:08:15Z","timestamp":1772946495225,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"publisher","award":["MDM-2017-0729"],"award-info":[{"award-number":["MDM-2017-0729"]}],"id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-116474RB-I00"],"award-info":[{"award-number":["PID2020-116474RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-106447RB-I00"],"award-info":[{"award-number":["PID2019-106447RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["2021SGR01086"],"award-info":[{"award-number":["2021SGR01086"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2023-146279OB-I00"],"award-info":[{"award-number":["PID2023-146279OB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00716","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T19:41:36Z","timestamp":1754509296000},"page":"e00716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients"],"prefix":"10.1016","volume":"22","author":[{"given":"Marta","family":"Garcia-Forn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Castany-Pladevall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Creus-Muncunill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantxa","family":"Golbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge\u00f2rgia","family":"Escaram\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uxue","family":"Balantzategi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Hernan-Godoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eul\u00e0lia","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"P\u00e9rez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00716_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington\u02bcs disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2025.e00716_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz230","article-title":"Increased translation as a novel pathogenic mechanism in Huntington's disease","volume":"142","author":"Creus-Muncunill","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00716_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/371762a0","article-title":"Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5\u2019-cap function","volume":"371","author":"Pause","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00716_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/15384101.2016.1151581","article-title":"4E-BP1, a multifactor regulated multifunctional protein","volume":"15","author":"Qin","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neurot.2025.e00716_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature11628","article-title":"Autism-related deficits via dysregulated eIF4E-dependent translational control","volume":"493","author":"Gkogkas","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00716_bib6","doi-asserted-by":"crossref","first-page":"15616","DOI":"10.1523\/JNEUROSCI.3888-10.2010","article-title":"Hypersensitivity to mGluR5 and ERK1\/2 leads to excessive protein synthesis in the hippocampus of a mouse model of Fragile X syndrome","volume":"30","author":"Osterweil","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurot.2025.e00716_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cell.2014.01.064","article-title":"Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in parkinson's disease","volume":"157","author":"Martin","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2025.e00716_bib8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1474-4422(20)30343-4","article-title":"Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies","volume":"19","author":"Wright","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00716_bib9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/mds.26001","article-title":"Genetic modifiers of Huntington's disease","volume":"29","author":"Gusella","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2025.e00716_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","article-title":"Huntington's disease: the current state of research with peripheral tissues","volume":"219","author":"Sassone","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2025.e00716_bib11","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1158\/0008-5472.CAN-09-4072","article-title":"The antidepressant sertraline inhibits translation initiation by curtailing Mammalian target of Rapamycin signaling","volume":"70","author":"Lin","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.neurot.2025.e00716_bib12","first-page":"3144","article-title":"7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington\u2019s disease mouse model through specific activation of the PLC\u03b31 pathway","volume":"26","author":"Garc\u00eda-D\u00edaz","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00716_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2025.e00716_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.biopsych.2014.05.015","article-title":"Coordinated messenger RNA\/microRNA changes in fibroblasts of patients with major depression","volume":"77","author":"Garbett","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00716_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2014.11.004","article-title":"Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease","volume":"74","author":"Tyebji","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00716_bib16","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1007\/s12035-018-0956-5","article-title":"Increased levels of rictor prevent mutant huntingtin-induced neuronal degeneration","volume":"55","author":"Creus-Muncunill","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurot.2025.e00716_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nbd.2018.08.024","article-title":"Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease","volume":"120","author":"Garc\u00eda-Forn","year":"2018","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00716_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012105","article-title":"Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington's disease","volume":"13","author":"Alcal\u00e1-Vida","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2025.e00716_bib19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1017\/S1461145714000534","article-title":"Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons","volume":"17","author":"Park","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2025.e00716_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature11782","article-title":"Exaggerated translation causes synaptic and behavioural aberrations associated with autism","volume":"493","author":"Santini","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00716_bib21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bbagen.2017.01.021","article-title":"Chelerythrine promotes Ca 2+-dependent calpain activation in neuronal cells in a PKC-independent manner","volume":"1861","author":"Saavedra","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.neurot.2025.e00716_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from Enroll-HD, a global clinical research platform for Huntington's disease","volume":"4","author":"Landwehrmeyer","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neurot.2025.e00716_bib23","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00702-024-02750-w","article-title":"The pathobiology of depression in Huntington\u2019s disease: an unresolved puzzle","volume":"131","author":"Jellinger","year":"2024","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurot.2025.e00716_bib24","series-title":"Linear mixed models for longitudinal data","author":"Verbeke","year":"2000"},{"key":"10.1016\/j.neurot.2025.e00716_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington's disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2025.e00716_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","article-title":"Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease","volume":"30","author":"Duan","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00716_bib27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0006-3223(98)00031-6","article-title":"Novel therapeutic approaches beyond the serotonin receptor","volume":"44","author":"Duman","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00716_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(99)00006-3","article-title":"Role of 5-HT2A receptors in the stress-induced down-regulation of brain-derived neurotrophic factor expression in rat hippocampus","volume":"262","author":"Vaidya","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2025.e00716_bib29","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurot.2025.e00716_bib30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38744","article-title":"Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease","volume":"7","author":"Arnoux","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.neurot.2025.e00716_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0264-9","article-title":"Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease","volume":"51","author":"Sanchis","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.neurot.2025.e00716_bib32","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","article-title":"FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease","volume":"23","author":"Di Pardo","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00716_bib33","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","article-title":"Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75 NTR up-regulation and astrocyte-mediated inflammation","volume":"24","author":"Miguez","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00716_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nbd.2015.09.001","article-title":"Prostaglandin E2 EP2 activation reduces memory decline in R6\/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity","volume":"95","author":"Anglada-Huguet","year":"2016","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00716_bib35","doi-asserted-by":"crossref","first-page":"32771","DOI":"10.1074\/jbc.M403528200","article-title":"Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte","volume":"279","author":"Chan","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2025.e00716_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbrc.2008.07.025","article-title":"AMPK represses TOP mRNA translation but not global protein synthesis in liver","volume":"374","author":"Reiter","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.neurot.2025.e00716_bib37","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jcb.24003","article-title":"Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation","volume":"113","author":"Yang","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.neurot.2025.e00716_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179283","article-title":"Metformin intake associates with better cognitive function in patients with Huntington's disease","volume":"12","author":"Herv\u00e1s","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00716_bib39","doi-asserted-by":"crossref","first-page":"22558","DOI":"10.3390\/ijms141122558","article-title":"Neuroprotective effects of psychotropic drugs in Huntington's disease","volume":"14","author":"Lauterbach","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2025.e00716_bib40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/brainsci11040413","article-title":"Longitudinal evaluation of the effect of tricyclic antidepressants and neuroleptics on the course of Huntington's Disease\u2014Data from a real world cohort","volume":"11","author":"Achenbach","year":"2021","journal-title":"Brain Sci"},{"key":"10.1016\/j.neurot.2025.e00716_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2022.111023","article-title":"The effects of antidepressants on depressive symptoms in manifest Huntington's disease","volume":"162","author":"Ogilvie","year":"2022","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.neurot.2025.e00716_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac278","article-title":"Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease","volume":"4","author":"McLauchlan","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurot.2025.e00716_bib43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00716_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.25750","article-title":"Results of the citalopram to enhance cognition in Huntington disease trial","volume":"29","author":"Beglinger","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2025.e00716_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1176\/appi.neuropsych.18120319","article-title":"A systematic review of neuropsychiatric symptoms and functional capacity in Huntington's disease","volume":"32","author":"Sellers","year":"2020","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.neurot.2025.e00716_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/mds.28363","article-title":"Measuring functional status in Huntington's Disease","volume":"36","author":"Gibson","year":"2021","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2025.e00716_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JHD-190391","article-title":"Baseline variables associated with functional decline in 2CARE, A randomized clinical trial in Huntington's disease","volume":"9","author":"McGarry","year":"2020","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.neurot.2025.e00716_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1176\/appi.neuropsych.21070191","article-title":"Apathy and depression in Huntington's disease: distinct longitudinal trajectories and clinical correlates","volume":"35","author":"Connors","year":"2023","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.neurot.2025.e00716_bib49","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.3390\/biomedicines11123336","article-title":"Factors influencing the total functional capacity Score as a critical endpoint in Huntington's disease research","volume":"11","author":"Achenbach","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurot.2025.e00716_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2022.11.020","article-title":"Longitudinal analysis of neuropsychiatric symptoms in a large cohort of early-moderate manifest Huntington's disease patients","volume":"106","author":"Ruiz-Idiago","year":"2023","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00716_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mds.28855","article-title":"An MDS evidence-based review on treatments for Huntington's Disease","volume":"37","author":"Ferreira","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2025.e00716_bib52","doi-asserted-by":"crossref","first-page":"e2407","DOI":"10.1212\/WNL.0000000000011823","article-title":"Association of CAG repeat length in the Huntington gene with cognitive performance in young adults","volume":"96","author":"Schultz","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00716_bib53","doi-asserted-by":"crossref","first-page":"8938","DOI":"10.1093\/nar\/gkr608","article-title":"CAG repeats mimic CUG repeats in the misregulation of alternative splicing","volume":"39","author":"Mykowska","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurot.2025.e00716_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1154","article-title":"Lamin B1 and nuclear morphology in peripheral cells as new potential biomarkers to follow treatment response in Huntington's disease","volume":"13","author":"Garcia-Forn","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.neurot.2025.e00716_bib55","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1093\/hmg\/ddi319","article-title":"HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism","volume":"14","author":"Seong","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00716_bib56","doi-asserted-by":"crossref","first-page":"21599","DOI":"10.1074\/jbc.M112.359307","article-title":"Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis","volume":"287","author":"Culver","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2025.e00716_bib57","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41556-024-01414-x","article-title":"Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington's disease","volume":"26","author":"Aviner","year":"2024","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.neurot.2025.e00716_bib58","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.molcel.2016.07.022","article-title":"Soluble oligomers of PolyQ-Expanded huntingtin target a multiplicity of key cellular factors","volume":"63","author":"Kim","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.neurot.2025.e00716_bib59","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.cell.2024.11.038","article-title":"Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease","volume":"188","author":"Handsaker","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2025.e00716_bib60","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41591-024-03424-6","article-title":"Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis","volume":"31","author":"Scahill","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00716_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/JHD-200426","article-title":"Modifiers of CAG\/CTG repeat instability: insights from Mammalian models","volume":"10","author":"Wheeler","year":"2021","journal-title":"J Huntingtons Dis"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:48:38Z","timestamp":1772894918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1878747925001941"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00716","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00716"}}